Resmed Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect Carol Burt, Jan De Witte, Christopher DelOrefice, Karen Drexler, Michael Farrell, Peter Farrell, Harjit Gill, John Hernandez, Nicole Mowad-Nassar, and Desney Tan to serve as directors until the 2027 annual meeting and until their successors are elected and qualified.

2. 2

   Ratification of Selection of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for Fiscal Year Ending June 30, 2027

   ManagementBoard: FOR

   Ratify the audit committee’s selection of PricewaterhouseCoopers LLP as ResMed’s independent registered public accounting firm for the fiscal year ending June 30, 2027.

3. 3

   Advisory Vote to Approve Named Executive Officer Compensation

   ManagementBoard: FOR

   Approve, on a non-binding advisory basis, the compensation paid to ResMed’s named executive officers as disclosed in the Compensation Discussion and Analysis and Executive Compensation Tables.

   More detail

   Proposal 3 asks stockholders to approve, on a non-binding advisory basis, the compensation paid to ResMed’s named executive officers. The vote covers the compensation philosophy, decisions, and amounts described in the Compensation Discussion and Analysis and executive compensation tables. Management is seeking approval under Section 14A of the Exchange Act, which requires a periodic advisory say-on-pay vote. ResMed emphasizes that its program is designed around pay for performance and long-term value creation. Approximately 91% of the CEO’s fiscal 2026 total compensation and an average of 84% of other NEO compensation were at risk through incentives and equity awards. Annual incentive payouts were 101.19% of target based on adjusted net sales and adjusted net operating profit, while significant performance stock unit value remained dependent on absolute and relative TSR. The company highlights that the CEO’s fiscal 2026 compensation actually paid under SEC calculations was negative $6.8 million because of declines in the company’s stock price and the value of outstanding awards. Stockholders approved the prior year’s say-on-pay proposal with approximately 90% support, up from approximately 84% the previous year, and the committee considered that feedback in its decisions. The board recommends voting FOR because it believes the program appropriately aligns executives with stockholders and supports sustainable long-term performance, while acknowledging that the advisory vote does not bind the board or company.

Upcoming shareholder meetings at Resmed Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Resmed Inc 2026 annual meeting?

Resmed Inc (RMD) holds its 2026 annual shareholder meeting on Wednesday, November 18, 2026.

What is the record date for the Resmed Inc 2026 meeting?

The record date for the Resmed Inc 2026 meeting is Tuesday, September 22, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Resmed Inc's 2026 meeting?

The board is presenting 10 director nominees at the Resmed Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Resmed Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Resmed Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.